GLAXOSMITHKLINE BIOLOGICALS : revenue, balance sheet and financial ratios

GLAXOSMITHKLINE BIOLOGICALS is a French company founded 39 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in SAINT-AMAND-LES-EAUX (59230), this company of category GE shows in 2024 a revenue of 174.4 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - GLAXOSMITHKLINE BIOLOGICALS (SIREN 338460017)
Indicator 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue 174 353 823 € 177 972 075 € 173 899 317 € 166 036 206 € 171 367 287 € 167 020 356 € 162 248 855 € 153 990 262 € 146 054 074 €
Net income 12 830 779 € 14 047 042 € 13 842 022 € 12 445 239 € 9 827 237 € 11 964 849 € 12 023 423 € 10 617 270 € 8 469 781 €
EBITDA 41 596 256 € 44 269 753 € 52 982 774 € 55 633 758 € 57 680 228 € 71 086 159 € 70 035 524 € 67 096 139 € 66 229 517 €
Net margin 7.4% 7.9% 8.0% 7.5% 5.7% 7.2% 7.4% 6.9% 5.8%

Revenue and income statement

In 2024, GLAXOSMITHKLINE BIOLOGICALS achieves revenue of 174.4 M€. Revenue is growing positively over 9 years (CAGR: +2.2%). Slight decline of -2% vs 2023. After deducting consumption (6.6 M€), gross margin stands at 167.7 M€, i.e. a rate of 96%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 41.6 M€, representing 23.9% of revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 12.8 M€, i.e. 7.4% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2024) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

174 353 823 €

Gross margin (2024) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

167 735 015 €

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

41 596 256 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

16 110 695 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

12 830 779 €

EBITDA margin (2024) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

23.8%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 79%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Cash flow represents 22.0% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

0.0%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

79.175%

Cash flow / Revenue (2024) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

21.961%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.0

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

27.4%

Solvency indicators evolution
GLAXOSMITHKLINE BIOLOGICALS

Sector positioning

Debt ratio
0.0 2024
2022
2023
2024
Q1: 0.0
Med: 5.92
Q3: 43.75
Excellent

In 2024, the debt ratio of GLAXOSMITHKLINE BIOLOGICALS (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.

Financial autonomy
79.17% 2024
2022
2023
2024
Q1: 28.05%
Med: 51.52%
Q3: 72.2%
Excellent -7 pts over 3 years

In 2024, the financial autonomy of GLAXOSMITHKLINE BIOLOGICALS (79.2%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Repayment capacity
0.0 years 2024
2022
2023
2024
Q1: 0.0 years
Med: 0.01 years
Q3: 1.74 years
Excellent

In 2024, the repayment capacity of GLAXOSMITHKLINE BIOLOGICALS (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 182.26. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 0.1x. Danger: operating income does not cover interest charges, unsustainable situation.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

182.265

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

0.136

Liquidity indicators evolution
GLAXOSMITHKLINE BIOLOGICALS

Sector positioning

Liquidity ratio
182.26 2024
2022
2023
2024
Q1: 120.09
Med: 209.86
Q3: 363.93
Average -33 pts over 3 years

In 2024, the liquidity ratio of GLAXOSMITHKLINE BIOLOGICALS (182.26) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Interest coverage
0.14x 2024
2022
2023
2024
Q1: 0.0x
Med: 1.78x
Q3: 10.15x
Average

In 2024, the interest coverage of GLAXOSMITHKLINE BIOLOGICALS (0.1x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 23 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 95 days. Excellent situation: suppliers finance 72 days of the operating cycle (retail model). Inventory turnover is 30 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 109 days of revenue, i.e. 52.7 M€ to permanently finance. Over 2016-2024, WCR increased by +248%, requiring additional financing.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

52 656 598 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

23 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

95 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

30 j

WCR in days of revenue (2024) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

109 j

WCR and payment terms evolution
GLAXOSMITHKLINE BIOLOGICALS

Positioning of GLAXOSMITHKLINE BIOLOGICALS in its sector

Comparison with sector Fabrication de préparations pharmaceutiques

Valuation estimate

Indicative estimate only : the number of comparable transactions in this sector is limited (27 transactions). This range of 2 559 987€ to 7 868 401€ is provided for information purposes only and requires in-depth analysis to be confirmed.

Estimated enterprise value 2024
Indicative
2559k€ 5779k€ 7868k€
5 779 707 € Range: 2 559 987€ - 7 868 401€
NAF 5 all-time
How is this estimate calculated?

This estimate is based on the analysis of 27 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Fabrication de préparations pharmaceutiques)

Compare GLAXOSMITHKLINE BIOLOGICALS with other companies in the same sector:

Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques

Frequently asked questions about GLAXOSMITHKLINE BIOLOGICALS

What is the revenue of GLAXOSMITHKLINE BIOLOGICALS ?

The revenue of GLAXOSMITHKLINE BIOLOGICALS in 2024 is 174.4 M€.

Is GLAXOSMITHKLINE BIOLOGICALS profitable?

Yes, GLAXOSMITHKLINE BIOLOGICALS generated a net profit of 12.8 M€ in 2024.

Where is the headquarters of GLAXOSMITHKLINE BIOLOGICALS ?

The headquarters of GLAXOSMITHKLINE BIOLOGICALS is located in SAINT-AMAND-LES-EAUX (59230), in the department Nord.

Where to find the tax return of GLAXOSMITHKLINE BIOLOGICALS ?

The tax return of GLAXOSMITHKLINE BIOLOGICALS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does GLAXOSMITHKLINE BIOLOGICALS operate?

GLAXOSMITHKLINE BIOLOGICALS operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.